Evidence map›Paper›PMID 36452209›Full record

ArticleFrontiers in bioengineering and biotechnology2022

An engineered hydrogel with low-dose antitumor drugs enhances tumor immunotherapy through tumor interstitial wrap.

Zhongxian Li, Jiawei Xiang, Qiang Zhang, Mingyuan Zhao, Yuan Meng, Jie Zhong, Tingting Li, Lanxin Jia, Kai Li, Xi Lu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Nanocarrier-Mediated Immunogenic Cell Death for Melanoma Treatment.International journal of nanomedicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Zhongxian LiCAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Jiawei XiangCAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Qiang ZhangHebei Key Lab of Nano-Biotechnology, Hebei Key Lab of Applied Chemistry, Yanshan University, Qinhuangdao, China.
Mingyuan ZhaoCAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Yuan MengCAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Jie ZhongCAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Tingting LiCollege of Life Sciences, Bejing University of Chinese Medicine, Beijing, China.
Lanxin JiaUniversity of Chinese Academy of Sciences, Beijing, China.
Kai LiCollege of Life Sciences, Bejing University of Chinese Medicine, Beijing, China.
Xi LuCollege of Life Sciences, Bejing University of Chinese Medicine, Beijing, China.
Zhuo AoCAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Dong HanCAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
University of Chinese Academy of Sciences · CNBeijing University of Chinese Medicine · CNChinese Academy of Sciences · CNNational Center for Nanoscience and Technology · CNYanshan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stimulating immunogenic cell death (ICD) is the key to tumor immunotherapy. However, traditional chemoradiotherapy has limited effect on stimulating immunity and often requires repeated administration, which greatly reduces the tumor-killing effect. In this article, we created a sodium alginate hydrogel sustained-release system containing low-dose doxorubicin (Dox) and immune adjuvant R837, which were injected into the interstitial space to wrap around the tumor

Indexed as

hydrogelimmunogenic cell deathinterstitial administrationtumor immunotherapytumor microenvironment

Identifiers

PMID36452209
PMCPMC9701709
OpenAlexW4309043400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.